These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 29900067)

  • 21. Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer.
    Matsumoto T; Okayama H; Nakajima S; Saito K; Nakano H; Endo E; Kase K; Ito M; Yamauchi N; Yamada L; Kanke Y; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Mimura K; Kono K
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
    Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
    J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LAG3 blockade coordinates with microwave ablation to promote CD8
    Shao D; Chen Y; Huang H; Liu Y; Chen J; Zhu D; Zheng X; Chen L; Jiang J
    J Transl Med; 2022 Sep; 20(1):433. PubMed ID: 36180876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.
    Pedroza-Gonzalez A; Verhoef C; Ijzermans JN; Peppelenbosch MP; Kwekkeboom J; Verheij J; Janssen HL; Sprengers D
    Hepatology; 2013 Jan; 57(1):183-94. PubMed ID: 22911397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphocyte-activated gene-3 (LAG3) protein expressed in tumor-infiltrating lymphocytes of colorectal cancer.
    Xu J; Shen D; Zhang T; Wang J; De W; Zhang J
    Pol J Pathol; 2021; 72(4):324-330. PubMed ID: 35308003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
    Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
    Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.
    Kanno H; Miyoshi H; Yoshida N; Sudo T; Nakashima K; Takeuchi M; Nomura Y; Seto M; Hisaka T; Tanaka H; Okuda K; Akagi Y; Ohshima K
    Cancer Sci; 2020 Aug; 111(8):3032-3044. PubMed ID: 32449240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases.
    Ahtiainen M; Elomaa H; Väyrynen JP; Wirta EV; Kuopio T; Helminen O; Seppälä TT; Kellokumpu I; Mecklin JP
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
    Llosa NJ; Luber B; Tam AJ; Smith KN; Siegel N; Awan AH; Fan H; Oke T; Zhang J; Domingue J; Engle EL; Roberts CA; Bartlett BR; Aulakh LK; Thompson ED; Taube JM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Anders RA; Housseau F
    Clin Cancer Res; 2019 Sep; 25(17):5250-5259. PubMed ID: 31061070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
    BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
    Smith KN; Llosa NJ; Cottrell TR; Siegel N; Fan H; Suri P; Chan HY; Guo H; Oke T; Awan AH; Verde F; Danilova L; Anagnostou V; Tam AJ; Luber BS; Bartlett BR; Aulakh LK; Sidhom JW; Zhu Q; Sears CL; Cope L; Sharfman WH; Thompson ED; Riemer J; Marrone KA; Naidoo J; Velculescu VE; Forde PM; Vogelstein B; Kinzler KW; Papadopoulos N; Durham JN; Wang H; Le DT; Justesen S; Taube JM; Diaz LA; Brahmer JR; Pardoll DM; Anders RA; Housseau F
    J Immunother Cancer; 2019 Feb; 7(1):40. PubMed ID: 30744692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
    van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
    Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.
    Solinas C; Garaud S; De Silva P; Boisson A; Van den Eynden G; de Wind A; Risso P; Rodrigues Vitória J; Richard F; Migliori E; Noël G; Duvillier H; Craciun L; Veys I; Awada A; Detours V; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
    Front Immunol; 2017; 8():1412. PubMed ID: 29163490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors.
    Toor SM; Sasidharan Nair V; Murshed K; Abu Nada M; Elkord E
    Vaccines (Basel); 2021 Jan; 9(1):. PubMed ID: 33477864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer.
    Rong YM; Xu YC; Chen XC; Zhong ME; Tan YX; Liang YF; Weng JR; Liu J; Wang XY; Luo DD; Bie YR; Chen X; Cai JW; Yu ZL; Zou YF
    Sci Rep; 2023 Nov; 13(1):20368. PubMed ID: 37989761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
    Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
    Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.